Sodium-glucose cotransporter-2 inhibitors showed similar effectiveness in reducing hepatic decompensation events compared to glucagon-like peptide-1 receptor agonists and a reduced risk compared to thiazolidinediones in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). A study conducted in Korea found that SGLT-2i users had a lower risk of decompensation events compared to TZD users and similar effectiveness compared to GLP-1RA users. The study also showed that SGLT-2i was more effective in women and patients under 65 years old. This highlights the potential benefits of SGLT-2i in managing liver disease in patients with MASLD, particularly in real-world settings.
Source link
Sodium-glucose inhibitors show similar hepatic effectiveness to GLP-1RAs in MASLD
